NCT04725877View on ClinicalTrials.gov

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

December 5, 2022

Study Completion Date

December 5, 2022

Conditions
HIV I Infection
Interventions
BIOLOGICAL

VIR-1111

VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.

DRUG

Placebo

A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.

Trial Locations (3)

33122

Investigative Site, Miami

53704

Investigative Site, Madison

98104

Investigative Site, Seattle

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Vir Biotechnology, Inc.

INDUSTRY

NCT04725877 - VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers | Biotech Hunter | Biotech Hunter